- |||||||||| HELICOBACTER PYLORI ERADICATION FIRST- AND SECOND-LINE REGIMENS PRESCRIPTIONS AND EFFECTIVENESS IN LITHUANIA DURING THE YEARS 2013-2023: ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG) (Science Lounge) - Jul 18, 2024 - Abstract #UEGW2024UEGW_1288;
Use of dual therapy gradually increased with years for HP eradication in the Chinese real-world clinical practice. The trends and effectiveness of other most frequent first- and second line prescriptions are presented in Table 1.First-line treatmentYears period2013-20162017-20202021-2023Prescriptionfrequency,n (% of top 5)Test post-treatment,n(follow-up %)mITT (95% CI)Prescriptionfrequency,n (% of top 5)Test post-treatment,n(follow-up %)mITT (95% CI)Prescriptionfrequency,n (% of top 5)Test post-treatment,n(follow-up %)mITT (95% CI)TripleC+AQuadrupleC+A+BTripleA+LTripleC+MQuadrupleA+M+B662(97.1%)0(0%)2(0.3%)18(2.6%)0(0%)301(45.5%)N/A1(50%)7(46.6%)N/A84.4%(80-88%)N/A100%(3-100%)100%(59-100%)N/A1477(89.5%)72(4.4%)35(2.1%)39(2.4%)27(1.6%)553(37.4%)20(27.8%)23(65.7%)14(95.9%)6(22.2%)85.7%(83-89%)100%(83-100%)100%(85-100%)92.9%(66-100%)83.3%(36-100%)686(68.5%)155(15.5%)11(1.1%)13(1.3%)137(13.7%)267(38.9%)35(8%)7(63.6%)8(61.5%)7(5.1%)93.3%(90-96%)88.6%(73-97%)100%(59-100%)87.5%(47-100%)100%(59-100%)Second-line treatmentYears period2013-20162017-20202021-2023Prescriptionfrequency,n (% of top 5)Test post-treatment,n(follow-up %)mITT (95% CI)Prescriptionfrequency,n (% of top 5)Test post-treatment,n(follow-up %)mITT (95% CI)Prescriptionfrequency,n (% of top 5)Test post-treatment,n(follow-up %)mITT (95% CI)QuadrupleA+L+BTripleA+LQuadrupleA+M+BTripleC+AQuadrupleC+A+B0(0%)57(79.2%)0(0%)15(20.8%)0(0%)N/A24(42.1%)N/A8(53.3%)N/AN/A87.5%(68-97%)N/A100%(63-100%)N/A110(39.4%)124(44.4%)21(7.5%)13(4.7%)11(3.9%)48(43.6%)84(67.7%)7(33.3%)9(69.2%)4(36.4%)97.9%(89-100%)91.7%(84-97%)71.4%(29-96%)100%(66-100%)100%(40-100%)167(65.2%)44(17.8%)32(12.5%)9(3.5%)11(4.3%)40(24%)26(59.1%)9(28.1%)5(55.6%)6(54.5%)95%(83-99%)96.2%(80-100%)88.9%(52-100%)100%(48-100%)83.3%(36-100%)mITT
- |||||||||| EFFECTIVENESS OF FIRST-LINE EMPIRICAL TREATMENT IN AZERBAIJAN: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG) (Science Lounge) - Jul 18, 2024 - Abstract #UEGW2024UEGW_1286;
The trends and effectiveness of other most frequent first- and second line prescriptions are presented in Table 1.First-line treatmentYears period2013-20162017-20202021-2023Prescriptionfrequency,n (% of top 5)Test post-treatment,n(follow-up %)mITT (95% CI)Prescriptionfrequency,n (% of top 5)Test post-treatment,n(follow-up %)mITT (95% CI)Prescriptionfrequency,n (% of top 5)Test post-treatment,n(follow-up %)mITT (95% CI)TripleC+AQuadrupleC+A+BTripleA+LTripleC+MQuadrupleA+M+B662(97.1%)0(0%)2(0.3%)18(2.6%)0(0%)301(45.5%)N/A1(50%)7(46.6%)N/A84.4%(80-88%)N/A100%(3-100%)100%(59-100%)N/A1477(89.5%)72(4.4%)35(2.1%)39(2.4%)27(1.6%)553(37.4%)20(27.8%)23(65.7%)14(95.9%)6(22.2%)85.7%(83-89%)100%(83-100%)100%(85-100%)92.9%(66-100%)83.3%(36-100%)686(68.5%)155(15.5%)11(1.1%)13(1.3%)137(13.7%)267(38.9%)35(8%)7(63.6%)8(61.5%)7(5.1%)93.3%(90-96%)88.6%(73-97%)100%(59-100%)87.5%(47-100%)100%(59-100%)Second-line treatmentYears period2013-20162017-20202021-2023Prescriptionfrequency,n (% of top 5)Test post-treatment,n(follow-up %)mITT (95% CI)Prescriptionfrequency,n (% of top 5)Test post-treatment,n(follow-up %)mITT (95% CI)Prescriptionfrequency,n (% of top 5)Test post-treatment,n(follow-up %)mITT (95% CI)QuadrupleA+L+BTripleA+LQuadrupleA+M+BTripleC+AQuadrupleC+A+B0(0%)57(79.2%)0(0%)15(20.8%)0(0%)N/A24(42.1%)N/A8(53.3%)N/AN/A87.5%(68-97%)N/A100%(63-100%)N/A110(39.4%)124(44.4%)21(7.5%)13(4.7%)11(3.9%)48(43.6%)84(67.7%)7(33.3%)9(69.2%)4(36.4%)97.9%(89-100%)91.7%(84-97%)71.4%(29-96%)100%(66-100%)100%(40-100%)167(65.2%)44(17.8%)32(12.5%)9(3.5%)11(4.3%)40(24%)26(59.1%)9(28.1%)5(55.6%)6(54.5%)95%(83-99%)96.2%(80-100%)88.9%(52-100%)100%(48-100%)83.3%(36-100%)mITT The prescribed H. pylori eradication regimens during the period 2020
- |||||||||| Mycobutin (rifabutin) / Pfizer, Lupin
EMPIRICAL SECOND-LINE TREATMENTS IN EUROPE: DATA FROM 9,000 CASES FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG) (Science Lounge) - Jul 18, 2024 - Abstract #UEGW2024UEGW_1282;
b.i.d.; high dose PPI Second-line empirical treatment prescriptions and effectiveness by treatment scheme and geographical region.TreatmentNUse (%)mITT, N (%)(95% CI)PP, N (%)(95% CI)Triple-A+LSingle-capsule*Quadruple-A+L+BQuadruple-C+A+MTriple-C+AQuadruple-M+Tc+BQuadruple-C+A+BTriple-A+MTriple-A+RTriple-A+MxOtherOverallOverall (optimised conditions)2,2121,7831,1705605254513702252121531,0138,6742,00525.520.613.56.56.15.24.32.62.41.811.510023.11,959 (81)**1,659 (88)**929 (85)534 (85)**424 (79)**405 (83)**251 (89)**198 (62)189 (83)147 (92)NA7,563 (83)1,747 (89)(79-83)(86-89)(83-87)(82-88)(75-83)(79-87)(85-93)(55-69)(77-88)(87-97)NA(82-84)(87-90)1,936 (81)1,621 (89)910 (85)523 (85)416 (79)386 (85)240 (90)195 (63)187 (83)147 (92)NA7,410 (83)1,709 (89)(79-83)(87-90)(83-88)(82-89)(75-83)(81-88)(86-94)(56-70)(77-89)(87-97)NA(83-84)(88-91)EastEast-CentreSouth-WestWest-CentreNorthTotal1,4251,6254,1901,1036318,97415.918.146.712.37.01001,159 (84)1,160 (84)3,973 (83)979 (84)547 (72)7,803 (83)(82-86)(82-86)(82-85)(82-87)(68-76)(82-84)1,121 (84)1,147 (84)3,895 (84)962 (85)530 (73)7,641 (83)(82-87)(82-87)(83-85)(82-87)(69-77)(83-84)95% CI
- |||||||||| HELICOBACTER PYLORI SECONDARY ANTIBIOTIC RESISTANCES: A GENOTYPIC STUDY ON STOOL SAMPLES (Science Lounge) - Jul 18, 2024 - Abstract #UEGW2024UEGW_1280;
Resistance to clarithromycin, amoxicillin, metronidazole, levofloxacin and tetracycline was assessed by high-resolution melting curve. In conclusion, our data seem to show that, despite secondary resistances are not so high, a resistance to clarithromycin could be very likely related to previous exposure to this antibiotic.
- |||||||||| levofloxacin / Generic mfg.
ESOPHAGEAL SQUAMOUS CELL PAPILLOMA: CASE REPORT AND CLINICAL INSIGHTS (Science Lounge) - Jul 18, 2024 - Abstract #UEGW2024UEGW_820;
The patient received a levofloxacin-based H. pylori eradication regimen, scheduled him for follow-up endoscopy in one year and he was referred to the Infectious Diseases Clinic for evaluation, where human papillomavirus infection and human immunodeficiency virus were excluded. Our case highlights esophageal squamous cell papilloma since this entity is rare and there are no clear guidelines available for treatment.
- |||||||||| pretomanid (PA-824) / Global Alliance for TB Drug Development, Sirturo (bedaquiline) / J&J, Pharmstandard
Journal: TB drug susceptibility testing in high fluoroquinolone resistance settings. (Pubmed Central) - Jul 18, 2024
Our case highlights esophageal squamous cell papilloma since this entity is rare and there are no clear guidelines available for treatment. The obtained results allowed designing the proposed diagnostic algorithm for rapid identification of DR-TB, ensuring rapid and equitable access to drug susceptibility testing for TB, ultimately improving TB care and control.
- |||||||||| levofloxacin / Generic mfg., clindamycin phosphate / Generic mfg., amoxycillin/clavulanate / Generic mfg.
Phase classification: Efficacy of Oral vs IV Antibiotics in the Treatment of Orofacial Osteomyelitis (clinicaltrials.gov) - Jul 17, 2024
P4, N=100, Not yet recruiting,
Further research is necessary to enhance our understanding of the varying correlations between virulence factors and outcomes of S. aureus BJIs. Phase classification: P --> P4
- |||||||||| Journal: Distribution Patterns and Antibiotic Resistance Profiles of Bacterial Pathogens Among Patients with Wound Infections in the Jiaxing Region from 2021 to 2023. (Pubmed Central) - Jul 15, 2024
More than half of the isolates were resistant to levofloxacin, ceftriaxone, cotrimoxazole, and gentamicin, with Acinetobacter baumannii strains showing considerable resistance (65.8-68.4%) to advanced cephalosporins and carbapenems...Independent risk factors included hyperglycemia, hypoalbuminemia, surgery, extended hospitalization, and polyantibiotic use. We urge prioritizing culture, susceptibility tests, and personalized antibiotic strategies to address MDRO risks and improve wound infection management specificity and efficacy.
- |||||||||| levofloxacin / Generic mfg.
Journal: Ignatzschineria indica Bacteremia Initially Misdiagnosed in a Patient With a Maggot-Infested Wound. (Pubmed Central) - Jul 9, 2024
After confirming the results, antibiotics were appropriately de-escalated to oral levofloxacin...Considering the increasing prevalence of chronic wounds in the United States, awareness and recognition of emerging pathogens are crucial for the timely diagnosis, treatment, and management of these complex patients. Our case adds to the growing body of reports on the management of I. indica bacteremia resulting from maggot-infested wounds.
- |||||||||| Journal: Operational research as a mechanism to improve treatment outcomes for drug-resistant TB in the WHO European Region. (Pubmed Central) - Jul 5, 2024
In 2022, the WHO European Region accounted for 15.1% of all incident rifampicin-resistant/multidrug-resistant TB (RR/MDR-TB) cases...The three regimens were: 1) bedaquiline + linezolid + levofloxacin + clofazimine + cycloserine (BdqLzdLfxCfzCs); 2) BdqLzdLfxCfz + delamanid (Dlm) for children over 6 years of age and adults; and 3) DlmLzdLfxCfz for children under 6 years of age...This unique experience promoted further collaboration with national tuberculosis programmes, health authorities, experts and donors within and outside Europe, with a focus on implementing operational research and improving the quality of care in high TB burden countries of the region. In the hope of encouraging others to adopt this model, we have described the principles of the initiative, its strengths and weaknesses and next steps.
- |||||||||| Medium chain fatty acids improve bacteriophage killing of Stenotrophomonas maltophilia (257 AB) - Jul 4, 2024 - Abstract #NACFC2024NACFC_641;
SCFAs inhibit S. maltophilia growth in a pH-dependent fashion, whereas MCFA growth inhibition is pH independent and synergistic with phages. Ongoing work focuses on understanding the mechanistic underpinnings of the beneficial MCFA interactions and exploring interactions between fatty acids and other S. maltophilia strains, phages, and antibiotics.
- |||||||||| Baxdela (delafloxacin) / Menarini, Melinta Therap, Taigexyn (nemonoxacin) / TaiGen
Clinical, Review: Together or Apart? Revealing the Impact of Dietary Interventions on Bioavailability of Quinolones: A Systematic Review with Meta-analyses. (Pubmed Central) - Jul 3, 2024
Several factors may influence interactions, including the physicochemical characteristics of quinolones, the type of intervention, drug formulation, and the patient's health status. We assessed the quality of evidence as low due to the poor actuality of included studies, their methodological diversity, and uneven data availability for individual drugs.
- |||||||||| Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Fetroja (cefiderocol) / Shionogi, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Genomic insights into NDM-1-producing Pseudomonas aeruginosa: Current status in a Bulgarian tertiary hospital and on the Balkans. (Pubmed Central) - Jul 2, 2024
In conclusion, to our knowledge this is the first report of blaNDM-1-positive P. aeruginosa ST611 isolation, which indicates the transmission dynamics of this determinant between high-risk and potentially high-risk P. aeruginosa clones. Obtained results unveil the dissemination of clonally related NDM-1-producing P. aeruginosa strains in the monitored hospital for approximately a 2-year period.
- |||||||||| levofloxacin / Generic mfg.
Journal: Severe Bacterial Pneumonia due to Legionella longbeachae Transmitted from Potting Soil in Japan. (Pubmed Central) - Jun 30, 2024
Although a urinary antigen test was negative for Legionella, he was clinically diagnosed with legionellosis and administered levofloxacin...Because the DNA of L. longbeachae was detected in the gardening soil, it is suspected source of infection. Therefore, it is important to suspect legionellosis based on clinical information, even if a urine antigen test is negative.
- |||||||||| Journal: Antibiotic-Resistance Profiles and Genetic Diversity of Shigella Isolates in China: Implications for Control Strategies. (Pubmed Central) - Jun 25, 2024
Conversely, Wuhan isolates displayed higher MDR and resistance to tetracycline, ciprofloxacin, levofloxacin, and cefepime relative to Xinjiang isolates...Six PFGE patterns (T1, T2, T5, T6-3, T8, and T10) of S. flexneri were associated with MDR. Thus, there is a critical need for robust surveillance and control strategies in managing Shigella infections, along with the development of targeted interventions and antimicrobial stewardship programs tailored to the distinct characteristics of Shigella isolates in different regions of China.
- |||||||||| levofloxacin / Generic mfg.
Preclinical, Journal: An antifouling supramolecular polymer ophthalmic ointment alleviates symblepharon in rat alkali burn eyes. (Pubmed Central) - Jun 25, 2024
Herein, an antifouling supramolecular polymer ophthalmic ointment consisting of poly(N-acryloyl alaninamide) (PNAAA), vitamin C (VitC) and levofloxacin (Levo) was developed (termed PNAVL ophthalmic ointment), which acted as a mucoadhesive and long-acting ocular delivery system. This antifouling PNAVL ophthalmic ointment improved the retention time of VitC and Levo, and simultaneously provided anti-inflammation and anti-fibrosis effects for mitigating symblepharon after ocular alkali burn injury.
- |||||||||| levofloxacin / Generic mfg.
Journal: Unraveling the role of toxin-antitoxin systems in Burkholderia pseudomallei: exploring bacterial pathogenesis and interactions within the HigBA families. (Pubmed Central) - Jun 25, 2024
We have previously studied the link between one of those systems (defined as HigBA) with specific expression patterns associated with levofloxacin antibiotic exposure...Toxin-antitoxin (TA) systems play a significant role in bacterial persistence, a phenomenon where bacterial cells enter a dormant or slow-growing state to survive adverse conditions such as nutrient deprivation, antibiotic exposure, or host immune responses. By studying TA systems in Burkholderia pseudomallei, we can gain insights into how this pathogen survives and persists in the host environment, contributing to its virulence and ability to cause melioidosis chronic infections.
- |||||||||| Journal, Real-world evidence, Real-world: Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data. (Pubmed Central) - Jun 24, 2024
Seven medications (stavudine, erlotinib, lenalidomide or thalidomide, chlorpromazine, metronidazole, prochlorperazine, and isoniazid) exhibited rates of 10.0 or more events per 10?000 person-years, and 10 (moxifloxacin, azathioprine, levofloxacin, clarithromycin, ketoconazole, fluconazole, captopril, amoxicillin-clavulanate, sulfamethoxazole-trimethoprim, and ciprofloxacin) had rates between 5.0 and 9.9 events per 10?000 person-years...In this study, incidence rates of severe ALI using real-world data identified the most potentially hepatotoxic medications and can serve as a tool to investigate hepatotoxicity safety signals obtained from case reports. Case report counts did not accurately reflect the observed rates of severe ALI after medication initiation.
|
